The minimal clinically important difference for the Sniffin’ Sticks Identification Test-16 in patients with chronic rhinosinusitis with nasal polyps treated with biologics
Authors:
Open Access
- 21 June 2026
- journal article
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 146 (10) , 1-9
Abstract
The Minimal Clinically Important Difference (MCID) reflects the smallest change in a test score perceived as relevant by the patient. MCIDs vary according to disease and clinical context. The Sniffin' Sticks Identification Test 16 (SSIT-16) is a commonly used smell assessment tool, but its MCID in severe chronic rhinosinusitis with nasal polyps (CRSwNP) is unknown. To determine the MCID of SSIT-16 in severe CRSwNP treated with biologics. We analysed change scores from baseline to week 24 in 313 patients. The MCID was estimated using anchor-based and distribution-based methods. Anchors included a visual analogue scale (VAS) for smell, the rhinologic domain of SNOT-22, and the smell/taste item of SNOT-22. Distribution-based analyses included half a standard deviation of baseline SSIT-16 scores, the standard error of measurement (SEM), and the individual-level smallest detectable change. The smell VAS performed best and was therefore chosen as the primary anchor. The optimal ΔSSIT-16 cut-off, balancing sensitivity (78%) and specificity (84%), was 3.5 points. This estimate was supported by distribution-based, sensitivity, and subgroup analyses. An improvement of approximately 3.5 SSIT-16 points appears to reflect clinically meaningful change in biologically treated patients with severe CRSwNP and may serve as a pragmatic threshold for interpreting olfactory outcomes.Keywords
Funding Information
- Simon Spies Fonden
- Thora og Viggo Groves Mindelegat
- Grosserer L.F. Foghts Fond
This publication has 17 references indexed in Scilit:
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Respiratory Medicine, 2021
- Cultural Adaptation and Validity of the Sniffin’ Sticks Psychophysical Test for the UK SettingChemosensory Perception, 2021
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trialsJournal of Allergy and Clinical Immunology, 2020
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Updated Sniffin’ Sticks normative data based on an extended sample of 9139 subjectsEuropean Archives of Oto-Rhino-Laryngology, 2018
- Danish validation of sniffin' sticks olfactory test for threshold, discrimination, and identificationThe Laryngoscope, 2017
- Investigating the minimal clinically important difference for SNOT‐22 symptom domains in surgically managed chronic rhinosinusitisInternational Forum of Allergy & Rhinology, 2017
- Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomesJournal of Clinical Epidemiology, 2008
- ‘Sniffin’ Sticks': Olfactory Performance Assessed by the Combined Testing of Odour Identification, Odor Discrimination and Olfactory ThresholdChemical Senses, 1997
- Measurement of health statusControlled Clinical Trials, 1989